FDA approves Replimune's Tudriqev melanoma drug on 3rd try
Asianet Newsable on MSN
Replimune’s first commercial drug arrives—with a 2027 cash cliff and 2030 finish line
Replimune’s Tudriqev was granted accelerated approval by the FDA earlier this week, following two prior complete response ...
Broad label to address high unmet need in advanced melanomaReplimune will host conference call on August 6, 2026 at 4:30 p.m. ET. WOBURN, ...
Replimune said the U.S. Food and Drug Administration granted accelerated approval for TUDRIQEV, previously known as RP1, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results